<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935530</url>
  </required_header>
  <id_info>
    <org_study_id>VTE-01</org_study_id>
    <nct_id>NCT02935530</nct_id>
  </id_info>
  <brief_title>Thromboprophylaxis After Surgery for Gynecologic Malignancy in China</brief_title>
  <official_title>Effectiveness and Safety of Thromboprophylaxis After Surgery for Gynecologic Malignancy in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venous thromboembolism (VTE) is an important cause of post-operative morbidity and mortality
      in women undergoing surgery for gynecologic malignancies. Although the benefit of
      thromboprophylaxis in reduction of post-operative VTE events after surgery for gynecologic
      cancers has been well documented around the world, the evidence for Chinese women is rare.
      The investigators designed this prospective and randomized study to assess the benefit of
      pharmacologic prophylaxis for patients received surgical treatment for gynecologic
      malignancies in China.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>VTE rate</measure>
    <time_frame>30-days from the date of operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding rate</measure>
    <time_frame>30-days from the date of operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rate</measure>
    <time_frame>30-days from the date of operation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Gynecologic Neoplasms</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Low Molecular Weight Heparin</condition>
  <condition>Argatroban</condition>
  <arm_group>
    <arm_group_label>s-LMWH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2125 I.U. subcutaneous injection for 5-10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LMWH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4250 I.U. subcutaneous injection for 5-10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Argatroban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg, injection for 5-10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>s-LMWH</intervention_name>
    <description>2125KU, subcutaneous injection of 5-10 days</description>
    <arm_group_label>s-LMWH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LMWH</intervention_name>
    <description>4250KU, subcutaneous injection of 5-10 days</description>
    <arm_group_label>LMWH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Argatroban</intervention_name>
    <description>20mg, injection for 5-10 days</description>
    <arm_group_label>Argatroban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of ovarian cancer, cervix cancer or endometrial cancer;

          -  Age ≤ 70 years; female, Chinese women;

          -  Initial treatment is surgery;

          -  Laboratory tests: WBC ≥ 4×10(9)/L, NEU ≥ 2×10(9)/L, PLT ≥ 100×10(9)/L, serum bilirubin
             ≤ 1.5 times the upper limit of normal, transaminase ≤ 1.5 times the upper limit of
             normal, BUN, Cr ≤ normal

          -  No prior pharmacologic prophylaxis;

          -  Provide written informed consent.

        Exclusion Criteria:

          -  PLT ≤ 75×10(9)/L

          -  Vascular injury

          -  History of thrombosis

          -  Liver and kidney dysfunction

          -  Concurrently participating in other clinical trials

          -  Unable or unwilling to sign informed consents;

          -  Unable or unwilling to abide by protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Danhui Weng, M.D.</last_name>
    <phone>027-83663351</phone>
    <email>dhweng@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danhui Weng, M.D.</last_name>
      <phone>027-83663351</phone>
      <email>dhweng@tjh.tjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Director of the department of Obstetrics and Gynecology, Tongji Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Argatroban</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

